Funds holding Monte Rosa Therapeutics Inc
ISIN US61225M1027 · United States
- Fund holders
- 211
- Of which ETFs
- 47 164 other funds
- Value held
- 387.2M $
- Share of capital
- 26.6 % of 85.3M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| PROFUND VP ULTRA SMALL CAP ProFunds | 202 | 3.3K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 153 | 2.5K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 136 | 2.2K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 110 | 2.1K $ | 0.03 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 107 | 1.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 82 | 1.3K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 48 | 852 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 39 | 641.6 $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 14 | 248.5 $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 13 | 213.9 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Longview Advantage ETF RBB Fund Trust | 6 | 106.5 $ | 0.00 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.87 % | as of Apr 30, 2026 ↗ |
| Small Cap Value Fund Northern Funds | 0.72 % | as of Mar 31, 2026 ↗ |
| First Trust Small Cap Growth AlphaDEX Fund First Trust Exchange-Traded AlphaDEX Fund | 0.65 % | as of Apr 30, 2026 ↗ |
| AlphaCentric Life Sciences and Healthcare Fund MUTUAL FUND SERIES TRUST | 0.53 % | as of Mar 31, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 0.51 % | as of Feb 28, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 0.49 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.44 % | as of Mar 31, 2026 ↗ |
| Invesco Dorsey Wright SmallCap Momentum ETF Invesco Exchange-Traded Fund Trust II | 0.43 % | as of Feb 28, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.42 % | as of Mar 31, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 0.42 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 211 | +24 | 22,667,084 | +48.9 % |
| 2026Q1 | 187 | +34 | 15,220,722 | +14.6 % |
| 2025Q4 | 153 | +1 | 13,276,540 | -8.1 % |
| 2025Q3 | 152 | +14 | 14,450,367 | -7.0 % |
| 2025Q2 | 138 | +7 | 15,535,892 | -6.8 % |
| 2025Q1 | 131 | +5 | 16,666,999 | +9.2 % |
| 2024Q4 | 126 | +3 | 15,259,833 | +5.1 % |
| 2024Q3 | 123 | -1 | 14,513,099 | +14.5 % |
| 2024Q2 | 124 | +1 | 12,671,946 | -0.3 % |
| 2024Q1 | 123 | -3 | 12,713,078 | -3.2 % |
| 2023Q4 | 126 | 13,129,578 |
Institutional managers
182 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| NEA Management Company, LLC | 7,692,298 | 126.5M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6,720,188 | 110.5K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 5,637,684 | 92.7M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 4,622,151 | 76M $ | as of Mar 31, 2026 |
| BVF INC/IL | 4,460,886 | 73.4M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 4,345,736 | 71.5M $ | as of Mar 31, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4,226,809 | 69.5M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 3,603,465 | 59.3M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 3,353,980 | 55.2M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 3,206,574 | 52.7M $ | as of Mar 31, 2026 |
| Versant Venture Management, LLC | 3,180,780 | 52.3M $ | as of Mar 31, 2026 |
| AMERICAN CENTURY COMPANIES INC | 2,809,647 | 46.2M $ | as of Mar 31, 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2,002,040 | 32.9M $ | as of Mar 31, 2026 |
| Aisling Capital Management LP | 1,555,664 | 25.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,540,812 | 25.4M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 1,433,152 | 23.6M $ | as of Mar 31, 2026 |
| Bellevue Group AG | 1,250,000 | 20.6M $ | as of Mar 31, 2026 |
| MPM BIOIMPACT LLC | 1,176,928 | 19.4M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,041,372 | 17.1M $ | as of Mar 31, 2026 |
| FMR LLC | 1,024,304 | 16.8M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,001,527 | 16.5M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 1,000,000 | 16.5M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 826,624 | 13.6M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 685,926 | 11.3M $ | as of Mar 31, 2026 |
| Alphabet Inc. | 684,275 | 11.3M $ | as of Mar 31, 2026 |
Declared shareholders of Monte Rosa Therapeutics Inc
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Baker Bros. Advisors LP and 3 others | 9.99 % | 8,876,346 | as of Mar 31, 2026 · SCHEDULE 13G |
| Adam Goulburn and 8 others | 8.10 % | 6,513,765 | as of Mar 31, 2026 · SCHEDULE 13G |
| BIOTECHNOLOGY VALUE FUND L P and 9 others | 6.30 % | 5,085,886 | as of Mar 31, 2026 · SCHEDULE 13G |
| TCG Crossover GP II, LLC and 4 others | 5.50 % | 4,622,151 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Monte Rosa Therapeutics Inc". https://titelia.com/en/stocks/monte-rosa-therapeutics-inc-US61225M1027